Oruka Therapeutics: Buy Rating Reaffirmed as EVERLAST-A Data Support Once-Yearly ORKA-001; $120 Price Target Maintained
at www.tipranks.com (Mon, 3-Aug 6:35 AM)
Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
at www.tipranks.com (Fri, 31-Jul 1:25 PM)
